Compare · LSTA vs SLS
LSTA vs SLS
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and SELLAS Life Sciences Group Inc. (SLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and SLS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SLS is the larger of the two at $1.60B, about 122.6x LSTA ($13.1M).
- LSTA has been more active in the news (8 items in the past 4 weeks vs 6 for SLS).
- SLS has more recent analyst coverage (1 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- SELLAS Life Sciences Group Inc.
- Price
- -
- -
- Market cap
- $13.1M
- $1.60B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 6
- Recent ratings
- 0
- 1
SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form S-3 filed by Lisata Therapeutics Inc.
- SEC Form S-8 filed by Lisata Therapeutics Inc.
- Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
- SEC Form DEF 14A filed by Lisata Therapeutics Inc.
- SEC Form 3 filed by Lisata Therapeutics Inc.
Latest SLS
- SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by SELLAS Life Sciences Group Inc.
- SEC Form SCHEDULE 13G filed by SELLAS Life Sciences Group Inc.
- SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
- SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
- SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
- SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update